Victrelis in the Spotlight for HIV/HCV-Coinfected Patients
By Barbara McGovern, M.D.
March 26, 2012
News from the latest major HIV research conference continues to look great for hepatitis C (HCV) cures.
The 12-week, "off-treatment" data show how much better triple therapy is than dual therapy. The percentage of patients who still had no detectable HCV in their blood was 61 percent in the triple-therapy group compared to 27 percent in the dual-therapy group.
The side effects were the same ones seen in the Victrelis trials that involved patients with HCV alone: mainly anemia (loss of red blood cells) and a bad taste in the mouth.
These encouraging results suggest that triple therapy is going to improve the treatment outcomes in coinfected patients by a wide margin. The final, 24-week post-treatment data will be presented later in the year. Bigger trials of triple therapy in HIV/HCV-coinfected patients are planned.
However, there is also the problem of drug interactions, which makes us remember that the treatment of HCV in the HIV-infected patient is certainly not straightforward, and we need to proceed with caution.
At CROI 2012, the maker of Victrelis showed data on drug interactions with HIV medications in 39 healthy volunteers. These persons were given one HIV protease inhibitor (e.g., Kaletra [lopinavir/ritonavir], Prezista [darunavir, TMC114] or Reyataz [atazanavir]) for about three weeks. Then they took the same HIV protease inhibitor in combination with Victrelis. Unfortunately, the combinations led to low blood levels of these HIV protease inhibitors. This can affect HIV control.
In addition, Kaletra and Prezista both cut down the levels of Victrelis. This can affect HCV treatment responses.
Meanwhile, in another study, the combination of Victrelis and the integrase inhibitor Isentress (raltegravir) did not lead to any drug interactions of concern.
So at this time, if you are taking Victrelis triple therapy and you are on an HIV protease inhibitor, contact your doctor to discuss these new study results -- but do so before you stop any of your medications, since stopping medications entirely may more quickly lead to resistance.
When you talk to your doctor, you may want to ask whether you need to switch around your HIV medications. Right now, Truvada (tenofovir/FTC) plus Isentress seems to be the safest bet among the standard first-line treatment options.
If you have questions about treating HIV/hepatitis C coinfection, Dr. McGovern is available to answer them! Visit our "Ask the Experts" forum on Hepatitis & HIV Coinfection to ask Dr. McGovern your question or browse her archive of answers.
Making Progress on HCV Treatment in HIV-Infected Patients
Barbara McGovern, M.D., is an associate professor of medicine at the Tufts University School of Medicine and an attending physician in the Division of Infectious Diseases at Lemuel Shattuck Hospital in Boston. She is a widely published researcher and frequent lecturer on issues pertaining to HIV and coinfections with hepatitis B and hepatitis C. More information about Dr. McGovern is available on her bio page.
Subscribe to Barbara's Blog:
A Brief Disclaimer:
The opinions expressed by TheBody.com's bloggers are entirely their own, and do not necessarily reflect the views of TheBody.com itself.